Telix Pharmaceuticals Limited is a radiopharmaceutical company that develops molecularly targeted radiation products for cancer care. The company is focused on developing diagnostic and therapeutic products using molecularly targeted radiation (MTR). Its lead products include TLX250, TLX250-CDx, TLX591, TLX591-CDx, and TLX101. Telix has strategic collaborations with RefleXion Medical, China Grand Pharmaceutical and Healthcare Holdings Limited, Mauna Kea Technologies, Kanazawa University, and Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia, with operations in Australia, Belgium, Japan, and the United States.